|
1
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al:
One hundred years after ‘carcinoid’: Epidemiology of and prognostic
factors for neuroendocrine tumors in 35,825 cases in the United
States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT
and Chang JS: The epidemiology of neuroendocrine tumors in Taiwan:
A nationwide cancer registry-based study. PLoS One. 8:e624872013.
View Article : Google Scholar
|
|
3
|
Modlin IM, Oberg K, Chung DC, Jensen RT,
de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA,
Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halfdanarson TR, Rabe KG, Rubin J and
Petersen GM: Pancreatic neuroendocrine tumors (PNETs): Incidence,
prognosis and recent trend toward improved survival. Ann Oncol.
19:1727–1733. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chamberlain RS, Canes D, Brown KT, Saltz
L, Jarnagin W, Fong Y and Blumgart LH: Hepatic neuroendocrine
metastases: Does intervention alter outcomes? J Am Coll Surg.
190:432–445. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Modlin IM, Lye KD and Kidd M: A 5-decade
analysis of 13,715 carcinoid tumors. Cancer. 97:934–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oberg K and Eriksson B: Endocrine tumours
of the pancreas. Best Pract Res Clin Gastroenterol. 19:753–781.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kulke MH, Shah MH, Benson AB III,
Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF,
Fanta P, Giordano T, et al; National Comprehensive Cancer Network.
Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw.
13:78–108. 2015.
|
|
9
|
Nave H, Mössinger E, Feist H, Lang H and
Raab H: Surgery as primary treatment in patients with liver
metastases from carcinoid tumors: A retrospective, unicentric study
over 13 years. Surgery. 129:170–175. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Capurso G, Bettini R, Rinzivillo M,
Boninsegna L, Delle Fave G and Falconi M: Role of resection of the
primary pancreatic neuroendocrine tumour only in patients with
unresectable meta-static liver disease: A systematic review.
Neuroendocrinology. 93:223–229. 2011. View Article : Google Scholar
|
|
11
|
Frilling A, Li J, Malamutmann E, Schmid
KW, Bockisch A and Broelsch CE: Treatment of liver metastases from
neuroendocrine tumours in relation to the extent of hepatic
disease. Br J Surg. 96:175–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frilling A, Modlin IM, Kidd M, Russell C,
Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain
V, et al; Working Group on Neuroendocrine Liver Metastases.
Recommendations for management of patients with neuroendocrine
liver metastases. Lancet Oncol. 15:e8–e21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martin-Perez E, Capdevila J, Castellano D,
Jimenez-Fonseca P, Salazar R, Beguiristain-Gomez A, Alonso-Orduña
V, Martinez Del Prado P, Villabona-Artero C, Diaz-Perez JA, et al:
The Large Experience of the Spanish National Tumor Registry
(RGETNE): Prognostic factors and long-term outcome of pancreatic
neuroendocrine neoplasms: Ki-67 index shows a greater impact on
survival than disease stage. The large experience of the Spanish
National Tumor Registry (RGETNE). Neuroendocrinology. 98:156–168.
2013. View Article : Google Scholar
|
|
14
|
Rindi G, Arnold R and Bosman FT:
Nomenclature and classification of neuroendocrine neoplasms of the
digestive system. WHO Classification of Tumours of the Digestive
System. Bosman FT, Carneiro F, Hruban RH and Theise ND: IARC,
Press; Lyon: 2010
|
|
15
|
Tang LH, Untch BR, Reidy DL, O'Reilly E,
Dhall D, Jih L, Basturk O, Allen PJ and Klimstra DS:
Well-differentiated neuroendocrine tumors with a morphologically
apparent high-grade component: A pathway distinct from poorly
differentiated neuroendocrine carcinomas. Clin Cancer Res.
22:1011–1017. 2016. View Article : Google Scholar
|
|
16
|
Garcia-Carbonero R, Sorbye H, Baudin E,
Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C,
Anlauf M, Cwikla JB, et al; Vienna Consensus Conference
participants. ENETS Consensus guidelines for high-grade
gastroenteropancreatic neuroendocrine Tumors and neuroendocrine
carcinomas. Neuroendocrinology. 103:186–194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldin SB, Bradner MW, Zervos EE and
Rosemurgy AS II : Assessment of pancreatic neoplasms: Review of
biopsy techniques. J Gastrointest Surg. 11:783–790. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rösch T, Lightdale CJ, Botet JF, Boyce GA,
Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H,
Schusdziarra V, et al: Localization of pancreatic endocrine tumors
by endoscopic ultrasonography. N Engl J Med. 326:1721–1726. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang KJ, Albers CG, Erickson RA, Butler
JA, Wuerker RB and Lin F: Endoscopic ultrasound-guided fine needle
aspiration of pancreatic carcinoma. Am J Gastroenterol. 89:263–266.
1994.PubMed/NCBI
|
|
20
|
Chatzipantelis P, Salla C, Konstantinou P,
Karoumpalis I, Sakellariou S and Doumani I: Endoscopic
ultrasound-guided fine-needle aspiration cytology of pancreatic
neuroendocrine tumors: A study of 48 cases. Cancer. 114:255–262.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jani N, Khalid A, Kaushik N, Brody D,
Bauer K, Schoedel K, Ohori NP, Moser AJ, Lee K and McGrath K:
EUS-guided FNA diagnosis of pancreatic endocrine tumors: New trends
identified. Gastrointest Endosc. 67:44–50. 2008. View Article : Google Scholar
|
|
22
|
Voss M, Hammel P, Molas G, Palazzo L,
Dancour A, O'Toole D, Terris B, Degott C, Bernades P and
Ruszniewski P: Value of endoscopic ultrasound guided fine needle
aspiration biopsy in the diagnosis of solid pancreatic masses. Gut.
46:244–249. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujimori N, Osoegawa T, Lee L, Tachibana
Y, Aso A, Kubo H, Kawabe K, Igarashi H, Nakamura K, Oda Y, et al:
Efficacy of endoscopic ultrasonography and endoscopic
ultrasonography-guided fine-needle aspiration for the diagnosis and
grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol.
51:245–252. 2016. View Article : Google Scholar
|
|
24
|
Hasegawa T, Yamao K, Hijioka S, Bhatia V,
Mizuno N, Hara K, Imaoka H, Niwa Y, Tajika M, Kondo S, et al:
Evaluation of Ki-67 index in EUS-FNA specimens for the assessment
of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy.
46:32–38. 2014.
|
|
25
|
Tyng CJ, Almeida MF, Barbosa PN,
Bitencourt AG, Berg JA, Maciel MS, Coimbra FJ, Schiavon LH, Begnami
MD, Guimarães MD, et al: Computed tomography-guided percutaneous
core needle biopsy in pancreatic tumor diagnosis. World J
Gastroenterol. 21:3579–3586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang RY, Ng D, Jaskolka JD, Rogalla P and
Sreeharsha B: Evaluation of percutaneous ultrasound-guided biopsies
of solid mass lesions of the pancreas: A center's 10-year
experience. Clin Imaging. 39:62–65. 2015. View Article : Google Scholar
|
|
27
|
Yu YP, Jiang HT, Yao Z, Xia QR, Hong FM,
Zeng H and Li S: Feasibility and safety of CT-guided percutaneous
needle biopsy and subsequent iodine-125 seed interstitial
implantation for pancreatic cancer. Zhonghua Zhong Liu Za Zhi.
35:608–612. 2013.(In Chinese). PubMed/NCBI
|
|
28
|
Karlson BM, Forsman CA, Wilander E,
Skogseid B, Lindgren PG, Jacobson G and Rastad J: Efficiency of
percutaneous core biopsy in pancreatic tumor diagnosis. Surgery.
120:75–79. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dhall D, Mertens R, Bresee C, Parakh R,
Wang HL, Li M, Dhall G, Colquhoun SD, Ines D, Chung F, et al: Ki-67
proliferative index predicts progression-free survival of patients
with well-differentiated ileal neuroendocrine tumors. Hum Pathol.
43:489–495. 2012. View Article : Google Scholar
|
|
30
|
Couvelard A, Deschamps L, Ravaud P, Baron
G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa
P, et al: Heterogeneity of tumor prognostic markers: A
reproducibility study applied to liver metastases of pancreatic
endocrine tumors. Mod Pathol. 22:273–281. 2009. View Article : Google Scholar
|
|
31
|
Zen Y and Heaton N: Elevated Ki-67
labeling index in ‘synchronous liver metastases’ of well
differentiated enteropancreatic neuroendocrine tumor. Pathol Int.
63:532–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Singh S, Hallet J, Rowsell C and Law CH:
Variability of Ki67 labeling index in multiple neuroendocrine
tumors specimens over the course of the disease. Eur J Surg Oncol.
40:1517–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grillo F, Albertelli M, Brisigotti MP,
Borra T, Boschetti M, Fiocca R, Ferone D and Mastracci L: Grade
increases in gastro-Enteropancreatic neuroendocrine tumor
metastases compared to the primary tumor. Neuroendocrinology.
103:452–459. 2015. View Article : Google Scholar
|
|
34
|
Singh S, Dey C, Kennecke H, Kocha W,
Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C, et
al: Consensus recommendations for the diagnosis and management of
pancreatic neuroendocrine tumors: Guidelines from a Canadian
National Expert group. Ann Surg Oncol. 22:2685–2699. 2015.
View Article : Google Scholar
|
|
35
|
Falconi M, Bartsch DK, Eriksson B, Klöppel
G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP and
O'Toole D; Barcelona Consensus Conference participants. ENETS
Consensus Guidelines for the management of patients with digestive
neuroendocrine neoplasms of the digestive system:
Well-differentiated pancreatic non-functioning tumors.
Neuroendocrinology. 95:120–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kulke MH, Anthony LB, Bushnell DL, de
Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier
RF, Yao JC, et al: North American Neuroendocrine Tumor Society
(NANETS): NANETS treatment guidelines: Well-differentiated
neuroendocrine tumors of the stomach and pancreas. Pancreas.
39:735–752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Öberg K, Knigge U, Kwekkeboom D and Perren
A; ESMO Guidelines Working Group. Neuroendocrine
gastro-enteropancreatic tumors: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7):
vii124–vii130. 2012.
|
|
38
|
Fischer L, Kleeff J, Esposito I, Hinz U,
Zimmermann A, Friess H and Büchler MW: Clinical outcome and
long-term survival in 118 consecutive patients with neuroendocrine
tumours of the pancreas. Br J Surg. 95:627–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pavel M, Baudin E, Couvelard A, Krenning
E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B and Salazar R;
Barcelona Consensus Conference participants. ENETS Consensus
Guidelines for the management of patients with liver and other
distant metastases from neuroendocrine neoplasms of foregut,
midgut, hindgut, and unknown primary. Neuroendocrinology.
95:157–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kunz PL, Reidy-Lagunes D, Anthony LB,
Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK,
Klimstra DS, et al; North American Neuroendocrine Tumor Society.
Consensus guidelines for the management and treatment of
neuroendocrine tumors. Pancreas. 42:557–577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. Springer; New
York, NY: 2010
|
|
42
|
Rindi G, Klöppel G, Alhman H, Caplin M,
Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M,
Komminoth P, et al; all other Frascati Consensus Conference
participants; European Neuroendocrine Tumor Society (ENETS). TNM
staging of foregut (neuro)endocrine tumors: A consensus proposal
including a grading system. Virchows Arch. 449:395–401. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Norton JA, Warren RS, Kelly MG, Zuraek MB
and Jensen RT: Aggressive surgery for metastatic liver
neuroendocrine tumors. Surgery. 134:1057–1063; discussion
1063–1065. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Elias D, Lasser P, Ducreux M, Duvillard P,
Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C,
et al: Liver resection (and associated extrahepatic resections) for
metastatic well-differentiated endocrine tumors: A 15-year single
center prospective study. Surgery. 133:375–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Watzka FM, Fottner C, Miederer M, Schad A,
Weber MM, Otto G, Lang H and Musholt TJ: Surgical therapy of
neuroendocrine neoplasm with hepatic metastasis: Patient selection
and prognosis. Langenbecks Arch Surg. 400:349–358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mayo SC, de Jong MC, Pulitano C, Clary BM,
Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB,
et al: Surgical management of hepatic neuroendocrine tumor
metastasis: Results from an international multi-institutional
analysis. Ann Surg Oncol. 17:3129–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Steinmüller T, Kianmanesh R, Falconi M,
Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao
J, et al; Frascati Consensus Conference participants. Consensus
guidelines for the management of patients with liver metastases
from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut,
and unknown primary. Neuroendocrinology. 87:47–62. 2008. View Article : Google Scholar
|
|
48
|
Sarmiento JM, Heywood G, Rubin J, Ilstrup
DM, Nagorney DM and Que FG: Surgical treatment of neuroendocrine
metastases to the liver: A plea for resection to increase survival.
J Am Coll Surg. 197:29–37. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kandil E, Noureldine SI, Koffron A, Yao L,
Saggi B and Buell JF: Outcomes of laparoscopic and open resection
for neuroendocrine liver metastases. Surgery. 152:1225–1231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dousset B, Saint-Marc O, Pitre J, Soubrane
O, Houssin D and Chapuis Y: Metastatic endocrine tumors: Medical
treatment, surgical resection, or liver transplantation. World J
Surg. 20:908–914; discussion 914–915. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kimura W, Tezuka K and Hirai I: Surgical
management of pancreatic neuroendocrine tumors. Surg Today.
41:1332–1343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hanazaki K, Sakurai A, Munekage M,
Ichikawa K, Namikawa T, Okabayashi T and Imamura M: Surgery for a
gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple
endocrine neoplasia type 1. Surg Today. 43:229–236. 2013.
View Article : Google Scholar
|
|
53
|
Bloomston M, Muscarella P, Shah MH,
Frankel WL, Al-Saif O, Martin EW and Ellison EC: Cytoreduction
results in high perioperative mortality and decreased survival in
patients undergoing pancreatectomy for neuroendocrine tumors of the
pancreas. J Gastrointest Surg. 10:1361–1370. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pavel M, O'Toole D, Costa F, Capdevila J,
Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et
al; Vienna Consensus Conference participants. ENETS consensus
guidelines update for the management of distant metastatic disease
of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN)
and NEN of unknown primary site. Neuroendocrinology. 103:172–185.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Maxwell JE, Sherman SK, O'Dorisio TM,
Bellizzi AM and Howe JR: Liver-directed surgery of neuroendocrine
metastases: What is the optimal strategy? Surgery. 159:320–333.
2016. View Article : Google Scholar
|
|
56
|
Gaujoux S, Gonen M, Tang L, Klimstra D,
Brennan MF, D'Angelica M, Dematteo R, Allen PJ, Jarnagin W and Fong
Y: Synchronous resection of primary and liver metastases for
neuroendocrine tumors. Ann Surg Oncol. 19:4270–4277. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zerbi A, Capitanio V, Boninsegna L, Delle
Fave G, Pasquali C, Rindi G, Campana D and Falconi M; AISP-Network
Study Group. Treatment of malignant pancreatic neuroendocrine
neoplasms: Middle-term (2-year) outcomes of a prospective
observational multicentre study. HPB Oxf. 15:935–943. 2013.
View Article : Google Scholar
|
|
58
|
Cusati D, Zhang L, Harmsen WS, Hu A,
Farnell MB, Nagorney DM, Donohue JH, Que FG, Reid-Lombardo KM and
Kendrick ML: Metastatic nonfunctioning pancreatic neuroendocrine
carcinoma to liver: Surgical treatment and outcomes. J Am Coll
Surg. 215:117–124; discussion 124–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mayo SC, de Jong MC, Bloomston M, Pulitano
C, Clary BM, Reddy SK, Clark Gamblin T, Celinski SA, Kooby DA,
Staley CA, et al: Surgery versus intra-arterial therapy for
neuroendocrine liver metastasis: A multicenter international
analysis. Ann Surg Oncol. 18:3657–3665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bettini R, Mantovani W, Boninsegna L,
Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P and Falconi M:
Primary tumour resection in metastatic nonfunctioning pancreatic
endocrine carcinomas. Dig Liver Dis. 41:49–55. 2009. View Article : Google Scholar
|
|
61
|
Sarmiento JM and Que FG: Hepatic surgery
for metastases from neuroendocrine tumors. Surg Oncol Clin N Am.
12:231–242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chambers AJ, Pasieka JL, Dixon E and
Rorstad O: The palliative benefit of aggressive surgical
intervention for both hepatic and mesenteric metastases from
neuroendocrine tumors. Surgery. 144:645–651; discussion 651–653.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hemming AW, Reed AI, Howard RJ, Fujita S,
Hochwald SN, Caridi JG, Hawkins IF and Vauthey JN: Preoperative
portal vein embolization for extended hepatectomy. Ann Surg.
237:686–691; discussion 691–693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yigitler C, Farges O, Kianmanesh R,
Regimbeau JM, Abdalla EK and Belghiti J: The small remnant liver
after major liver resection: How common and how relevant? Liver
Transpl. 9:S18–S25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Goessmann H, Lang SA, Fichtner-Feigl S,
Scherer MN, Schlitt HJ, Stroszczynski C, Schreyer AG and
Schnitzbauer AA: Biliodigestive anastomosis: Indications,
complications and interdisciplinary management. Chirurg.
83:1097–1108. 2012.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kianmanesh R, Sauvanet A, Hentic O,
Couvelard A, Lévy P, Vilgrain V, Ruszniewski P and Belghiti J:
Two-step surgery for synchronous bilobar liver metastases from
digestive endocrine tumors: A safe approach for radical resection.
Ann Surg. 247:659–665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schnitzbauer AA, Lang SA, Goessmann H,
Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T,
Goralcyk A, Hörbelt R, et al: Right portal vein ligation combined
with in situ splitting induces rapid left lateral liver lobe
hypertrophy enabling 2-staged extended right hepatic resection in
small-for-size settings. Ann Surg. 255:405–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Glazer ES, Tseng JF, Al-Refaie W,
Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN and Curley
SA: Long-term survival after surgical management of neuroendocrine
hepatic metastases. HPB Oxf. 12:427–433. 2010. View Article : Google Scholar
|
|
69
|
Taner T, Atwell TD, Zhang L, Oberg TN,
Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM and Que FG:
Adjunctive radiofrequency ablation of metastatic neuroendocrine
cancer to the liver complements surgical resection. HPB Oxf.
15:190–195. 2013. View Article : Google Scholar
|
|
70
|
Frilling A and Clift AK: Therapeutic
strategies for neuroendocrine liver metastases. Cancer.
121:1172–1186. 2015. View Article : Google Scholar
|
|
71
|
Frilling A, Sotiropoulos GC, Li J,
Kornasiewicz O and Plöckinger U: Multimodal management of
neuroendocrine liver metastases. HPB Oxf. 12:361–379. 2010.
View Article : Google Scholar
|
|
72
|
Jagannath P, Chhabra D, Shrikhande S and
Shah R: Surgical treatment of liver metastases in neuroendocrine
neoplasms. Int J Hepatol. 2012:7826722012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bertani E, Fazio N, Botteri E, Chiappa A,
Falconi M, Grana C, Bodei L, Papis D, Spada F, Bazolli B, et al:
Resection of the primary pancreatic neuroendocrine tumor in
patients with unresectable liver metastases: Possible indications
for a multimodal approach. Surgery. 155:607–614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nguyen SQ, Angel LP, Divino CM, Schluender
S and Warner RR: Surgery in malignant pancreatic neuroendocrine
tumors. J Surg Oncol. 96:397–403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Basturk O, Yang Z, Tang LH, Hruban RH,
Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, et
al: The high-grade (WHO G3) pancreatic neuroendocrine tumor
category is morphologically and biologically heterogenous and
includes both well differentiated and poorly differentiated
neoplasms. Am J Surg Pathol. 39:683–690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Heetfeld M, Chougnet CN, Olsen IH, Rinke
A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D and Walter
T; other Knowledge Network members. Characteristics and treatment
of patients with G3 gastroenteropancreatic neuroendocrine
neoplasms. Endocr Relat Cancer. 22:657–664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ilett EE, Langer SW, Olsen IH, Federspiel
B, Kjær A and Knigge U: Neuroendocrine carcinomas of the
gastroenteropancreatic system: A comprehensive review. Diagnostics
Basel. 5:119–176. 2015. View Article : Google Scholar
|
|
78
|
Panzuto F, Boninsegna L, Fazio N, Campana
D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L,
Tomassetti P, et al: Metastatic and locally advanced pancreatic
endocrine carcinomas: Analysis of factors associated with disease
progression. J Clin Oncol. 29:2372–2377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM,
Kim WH, Kim H, Kook MC, Park DY, Lee JH, et al; Gastrointestinal
Pathology Study Group of Korean Society of Pathologists. Current
Trends of the Incidence and Pathological Diagnosis of
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea
2000–2009 Multicenter Study. Cancer Res Treat. 44:157–165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Strosberg JR, Coppola D, Klimstra DS, Phan
AT, Kulke MH, Wiseman GA and Kvols LK; North American
Neuroendocrine Tumor Society (NANETS). The NANETS consensus
guidelines for the diagnosis and management of poorly
differentiated (high-grade) extrapulmonary neuroendocrine
carcinomas. Pancreas. 39:799–800. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nilsson O, Van Cutsem E, Delle Fave G, Yao
JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Keleştimur
F, Sauvanet A, et al; Frascati Consensus Conference; European
Neuroendocrine Tumor Society. Poorly differentiated carcinomas of
the foregut (gastric, duodenal and pancreatic). Neuroendocrinology.
84:212–215. 2006. View Article : Google Scholar
|
|
82
|
Akerström G: Management of carcinoid
tumors of the stomach, duodenum, and pancreas. World J Surg.
20:173–182. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kölby L, Nilsson O and Ahlman H:
Gastroduodenal endocrine tumours. Scand J Surg. 93:317–323.
2004.
|
|
84
|
Du S, Ni J, Weng L, Ma F, Li S, Wang W,
Sang X, Lu X, Zhong S and Mao Y: Aggressive locoregional treatment
improves the outcome of liver metastases from grade 3
gastroenteropancreatic neuroendocrine tumors. Medicine (Baltimore).
94:e14292015. View Article : Google Scholar
|
|
85
|
Haugvik SP, Janson ET, Österlund P, Langer
SW, Falk RS, Labori KJ, Vestermark LW, Gr⊘nbæk H, Gladhaug IP and
Sorbye H: Surgical treatment as a principle for patients with
high-grade pancreatic neuroendocrine carcinoma: A Nordic
multicenter comparative study. Ann Surg Oncol. 23:1721–1728. 2016.
View Article : Google Scholar
|
|
86
|
Schweizer RT, Alsina AE, Rosson R and
Bartus SA: Liver transplantation for metastatic neuroendocrine
tumors. Transplant Proc. 25:19731993.PubMed/NCBI
|
|
87
|
Lehnert T: Liver transplantation for
metastatic neuroendocrine carcinoma: An analysis of 103 patients.
Transplantation. 66:1307–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Olausson M, Friman S, Herlenius G, Cahlin
C, Nilsson O, Jansson S, Wängberg B and Ahlman H: Orthotopic liver
or multivisceral transplantation as treatment of metastatic
neuroendocrine tumors. Liver Transpl. 13:327–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Frilling A, Malago M, Weber F, Paul A,
Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A,
Mueller-Brand J, et al: Liver transplantation for patients with
metastatic endocrine tumors: Single-center experience with 15
patients. Liver Transpl. 12:1089–1096. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
van Vilsteren FG, Baskin-Bey ES, Nagorney
DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ and Hobday TJ:
Liver transplantation for gastroenteropancreatic neuroendocrine
cancers: Defining selection criteria to improve survival. Liver
Transpl. 12:448–456. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rosenau J, Bahr MJ, von Wasielewski R,
Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP and
Boeker KH: Ki67, E-cadherin, and p53 as prognostic indicators of
long-term outcome after liver transplantation for metastatic
neuroendocrine tumors. Transplantation. 73:386–394. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Le Treut YP, Grégoire E, Klempnauer J,
Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O,
Mantion G, et al; For ELITA. Liver transplantation for
neuroendocrine tumors in Europe-results and trends in patient
selection: A 213-case European liver transplant registry study. Ann
Surg. 257:807–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Mazzaferro V, Pulvirenti A and Coppa J:
Neuroendocrine tumors metastatic to the liver: How to select
patients for liver transplantation? J Hepatol. 47:460–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
